Successful treatment of mucous membrane pemphigoid with infliximab.
Heffernan
Michael P
MP
Divisions of Dermatology, Wright State University School of Medicine, Dayton, Ohio 45408-1445, USA. michael.heffernan@wright.edu
Bentley
Danette D
DD
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003229:Conjunctival Diseases / Q000150:complications / Q000601:surgery; D016039:Corneal Transplantation; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D000069285:Infliximab; D010390:Pemphigoid, Benign Mucous Membrane / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab